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The receptor for interleukin-5 (IL-5R) is composed of a
unique a chain (IL-5Ra) expressed on eosinophils and
basophils, associated with a bc subunit, which is shared
by the receptors for IL-3 and granulocyte macrophage-
colony stimulating factor. One of the molecular events
activated via the IL-5R is the JAK/STAT signaling path-
way. Recent reports have shown that IL-5 induces tyro-
sine phosphorylation of JAK2 followed by the subse-
quent cell type-specific activation of either STAT1a or
STAT5. To identify additional STAT proteins activated
by IL-5, we co-transfected the IL-5Rwith STAT cDNAs in
COS cells. We found that IL-5 induces binding of STAT3
to the intercellular adhesion molecule-1 pIRE, and acti-
vates STAT3-dependent transcription. Moreover, endog-
enous STAT3 was tyrosine phosphorylated and acti-
vated in human IL-5-stimulated BaF3 cells ectopically
expressing the human IL-5R (BaF3/IL5R). These data
imply that multiple STAT proteins are involved in gene
regulation by IL-5 in a cell type-specific manner. We
further demonstrate using C-terminal truncations of the
a and bc subunits of the IL-5R that the membrane-prox-
imal regions of both subunits are required for STAT
activation. Interestingly, a bc receptor mutant lacking
intracellular tyrosine residues is able to mediate STAT3
activation, suggesting that tyrosine phosphorylation of
the bc receptor is not essential for STAT3 activation.
Hematopoiesis is tightly regulated by a complex network of
stromal interactions and by soluble polypeptide factors named
cytokines. IL-3,1 IL-5, and GM-CSF are cytokines that have
diverse effects on the proliferation, differentiation, and activa-
tion of blood cells and their precursors (1–3). Whereas IL-3 and
GM-CSF also have effects on other hematopoietic lineages (3,
4), the effect of IL-5 in humans is restricted to eosinophils and
basophils. IL-5 is essential for eosinophil differentiation (5, 6)
and plays an important role in the function of mature eosino-
phils (7–11). The specific effects of IL-5 on eosinophils and
basophils are due to restricted expression of the low affinity
IL-5Ra receptor on these cell types (12, 13). The high affinity
receptor for IL-5 (IL-5R) is composed of a unique a subunit
associated with a bc subunit that is shared with the receptors
for IL-3 and GM-CSF (14). The bc subunit is essential for signal
transduction (15, 16), but also, the a chain transduces intra-
cellular growth signals (17). Therefore, the common use of the
bc subunit by IL-3, IL-5, and GM-CSF explains the partial
observed functional redundancy of these cytokines (16, 18).
However, postreceptor signal transduction pathways are not
well defined and are likely to be composed of both mitogenic
and differentiation signals. It is known that the bc subunit, like
other cytokine receptors, does not contain intrinsic tyrosine
kinase activity (19, 20). However, one of the earliest events to
occur after IL-3, IL-5, and GM-CSF stimulation is induction of
protein tyrosine phosphorylation (19, 21). This tyrosine phos-
phorylation is caused by the activation of several cytoplasmic
protein tyrosine kinases such as Lyn (22, 23) and c-Fps/Fes
(24). Recent studies have demonstrated that the family of Ja-
nus kinases (JAKs), containing four members (JAK1, JAK2,
JAK3, and TYK2), is associated with different cytokine recep-
tors and is phosphorylated after ligand binding (25). We and
others have shown that only JAK2 is activated in response to
IL-3, IL-5, and GM-CSF (26–28) and specifically associates
with the membrane-proximal region of the b chain (29). The
JAK protein-tyrosine kinases activate members of a novel fam-
ily of transcription factors named signal transducers and acti-
vators of transcription (STATs) (25).
STAT proteins were first described as intermediates in the
interferon-a/b (IFN-a/b) signaling pathway (30, 31). At pres-
ent, eight different STATs (STAT1a, STAT1b, STAT2, STAT3,
STAT4, STAT5A, STAT5B, STAT6) have been described and
are involved in specific cytokine regulation. (31–39). This fam-
ily of STAT proteins comprises a new class of transcription
factors that contain Src homology 2 (SH2), SH3-like domains,
and a carboxyl-terminal tyrosine phosphorylation site (25).
STAT proteins normally exist as inactive monomers in the
cytoplasm, but after phosphorylation on tyrosine, they form
homo- or heterodimers, which translocate to the nucleus and
bind to specific DNA motifs (40–44). We recently found that
STAT3 is also phosphorylated on serine residues (45). This
serine phosphorylation seems to be necessary for the regulation
of the transactivation potential of STAT3.
We have previously shown that IL-5 activates STAT1a to-
gether with an unidentified DNA-binding protein in human
eosinophils (27). Therefore, we were interested whether other
known STAT proteins can be activated by IL-5. For this pur-
pose, we reconstituted both subunits of the IL-5 receptor to-
gether with different STAT cDNAs in COS cells. We demon-
strated that besides STAT1a, STAT3 was also activated by IL-5
in these transfected COS cells. In addition, endogenous STAT3
was tyrosine phosphorylated and activated by hIL-5 in BaF3
cells stably expressing the hIL-5R (BaF3/IL5R). Finally we
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demonstrate, using carboxyl-terminal truncations of both the a
and b subunits, that the membrane-proximal region of both
subunits are necessary for STAT3 activation.
MATERIALS AND METHODS
Cell Culture, Reagents, and Antibodies—Monkey COS-1 cells were
cultured in Dulbecco’s modified Eagle’s medium (Life Technologies,
Inc.) supplemented with 10% heat inactivated fetal calf serum. A mouse
IL-3-dependent pro-B cell line, BaF3, and BaF3 cells expressing the
wild type human IL-5 receptor a and b subunits (BaF3/IL5R) were
maintained in RPMI 1640 supplemented with 10% Hyclone serum and
the appropriate cytokine. Parental BaF3 cells were grown in medium
with 10210 M mouse IL-3 (Genzyme, Cambridge, MA), BaF3/IL5R cells
were grown in medium with 10210 M hIL-5 (a kind gift of Dr. D. Fattah,
Glaxo Group Research, Greenford, United Kingdom) and 1 mg/ml G418
(Life Technologies, Inc.). Anti-phosphotyrosine monoclonal antibody
(4G10) was obtained from UBI (Lake Placid, NY). The monoclonal
antibody directed against STAT1a/b was purchased from Transduction
Laboratories (Lexington, Kentucky). The STAT3 rabbit polyclonal an-
tibody was obtained from Santa Cruz Biotechnology (Santa Cruz,
California).
Synthetic Oligonucleotides and Plasmid Construction—Oligonucleo-
tides with the following sequences were used in this study (only the top
strands are shown): the human ICAM-1 pIRE, 59-AGCTTAGGTTTC-
CGGGAAAGCAC-39; a mutant pIRE, 59-AGGCGCGAGGTTAGCGGT-
CAAGCAGCACCGC-39; the c-fos SIEm67, 59-GTGCATTTCCCGTA-
AATCTTGTCTACAATTC-39; and the FcgRI GRR, 59-AGCTTGA-
GATGTATTTCCCAGAAAAGA-39. The 2xpIREtkluc reporter construct
has been described by us previously (43); also the pSV-lacZ expression
vector has been described previously (46). The reporter plasmids
4xIREtkCAT and 4xGRRtkCAT were constructed by cloning four oligo-
nucleotides containing either the pIRE or GRR in the HindIII site
upstream of the thymidine kinase minimal promoter in pBLCAT2.
pSGhSTAT1a was constructed by inserting the cDNA for human
STAT1a from pMNC91 (47) into the NotI/BamHI sites of pSG513 (48).
pSGhSTAT3 was constructed by inserting the human STAT3 cDNA
isolated from a human eosinophil cDNA library into PSG513. pSGm-
STAT4 was constructed by inserting the cDNA for mouse STAT4 from
Rc/CMV-STAT4 (32) into the HindIII/SmaI sites of pSG513. pSGsh-
STAT5 was constructed by inserting the cDNA for sheep STAT5 (MGF)
from pXM-STAT5 (49) into the HindIII/NotI sites of pSG513. pSGh-
STAT6 was constructed by inserting the cDNA for human STAT6
(IL-4STAT) from TPU231 (38) into the EcoRI/XhoI sites of pSG513.
pSGhIL5Ra was constructed by inserting the cDNA for the human
IL-5a receptor from pBKhIL5Ra (50) into the NotI/KpnI sites of
pSG513. pSGhIL5Rb was constructed by inserting the cDNA for the
human bc subunit from pSV532 (14) into the EcoRI sites of pSG513. For
construction of the c-terminal deletions of the IL-5 receptor a and b
chains, stop codons where introduced at the indicated amino acids using
PCR.
Generation of Stable Transfectants—Plasmid DNAs of the human
IL-5Ra and bc containing the neomycin resistance gene were trans-
fected into the BaF3 cells by using electroporation as described previ-
ously (21), and transfectants were selected using G418 (1 mg/ml). Ex-
pression of the a and bc subunits was verified by PCR analysis and by
growth in the presence of hIL-5.
Transient Transfection—For transfection experiments, COS cells
were split 1:3 in 6-well plates (Costar), and 2 h later the cells were
transfected with 10 mg of supercoiled plasmid DNA by the calcium
phosphate coprecipitation technique (51). Following 16–20 h of expo-
sure to the calcium-phosphate precipitate, medium was refreshed, and
cells were incubated for 16 h with IL-5. Transfected cells were subse-
quently harvested for luciferase assay (52) and lacZ determination (53).
Gel Retardation Assay—Nuclear extracts were prepared from un-
stimulated and stimulated COS and BaF3 cells following a previously
described procedure (54). Oligonucleotides were labeled by filling in the
cohesive ends with [a-32P]dCTP using Klenow fragment of DNA polym-
erase I. Gel retardation assays were carried out according to published
procedures with slight modifications (30). Briefly, nuclear extracts (10
mg) were incubated in a final volume of 20 ml, containing 10 mMHEPES,
pH 7.8, 50 mM KCL, 1 mM EDTA, 5 mM MgCl2, 10% (v/v) glycerol, 5 mM
dithiothreitol, 2 mg of poly(dI-dC) (Pharmacia Biotech Inc.), 20 mg of
bovine serum albumin, and 1.0 ng of 32P-labeled ICAM1-pIRE oligonu-
cleotide for 20 min at room temperature. In competition experiments,
extracts were incubated for 5 min with the indicated molar excess of
unlabeled oligonucleotide prior to the addition of labeled oligonucleo-
tide. Identification of the different DNA binding proteins was per-
formed by preincubating nuclear extracts for 30 min on ice with anti-
sera before addition of the probe.
Immunoprecipitation and Western Blotting—Unstimulated and IL-5
stimulated BaF3 cells were incubated with lysis buffer (20 mM Tris, pH
7.4, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxy-
cholate, 5 mM EDTA, Na3VO4, 10 mg/ml aprotinine, 1 mM phenylmeth-
ylsulfonylfluoride, 1 mM leupeptin) for 15 min on ice. The lysate was
centrifuged to remove nuclei and cellular debris. The cell lysates were
incubated with the anti-STAT3 polyclonal antibody for 1 h at 4 °C.
Immune complexes were then precipitated with protein A-Sepharose
for 1 h at 4 °C, washed 3 times with lysis buffer, and boiled in 1.0 3
Laemmli’s sample buffer. The proteins were electrophoresed on a SDS-
polyacrylamide gel and transferred to nitrocellulose membrane. After
blocking in TBST (150 mM NaCl, 10 mM Tris, pH 8.0, 0.3% Tween 20)
with 5% bovine serum albumin, the membrane was either incubated
with the anti-phosphotyrosine (4G10) monoclonal antibody or with the
polyclonal anti-STAT3 antibody. Between the incubation with 4G10
and STAT3 antibodies, the membrane was stripped with 1% SDS, 30
mM Tris, pH 8.0, 50 mM b-mercaptoethanol for 2 3 15 min at 55 °C.
After washing 3 times with TBST, the membrane was incubated for 1 h
with peroxidase-conjugated rabbit anti-mouse or swine anti-rabbit an-
tibodies, respectively. In both cases, the membrane was washed 5 times
with TBST, and immunoprecipitated proteins were visualized with
enhanced chemiluminescence (ECL, Amersham Corp.).
RESULTS
Reconstitution of the IL-5 Receptor in COS Cells Results in
STAT3 Activation by IL-5—We have previously shown that
IL-5 treatment of human eosinophils activates the binding of
multiple protein complexes to the pIRE from the ICAM-1 pro-
moter (27). We also demonstrated that one of these complexes
contained STAT1a (p91) by using STAT1a specific antibodies.
However, the identity of the other DNA-binding proteins acti-
vated by IL-5 remained unknown. One approach to define
whether IL-5 can also activate other known members of the
STAT family is to reconstitute STAT activation by IL-5 in COS
cells. We therefore transiently transfected these cells with ex-
pression vectors encoding the human IL-5Ra and IL-5Rb sub-
units in combination with expression vectors encoding the dif-
ferent STATmembers. These were co-transfected together with
a reporter construct containing 2 pIRE sequences coupled to
the thymidine kinase (tk) promoter and the luciferase (luc)
gene (2xpIREtkluc). We previously identified this pIRE se-
quence from the ICAM-1 promoter to bind IL-6- and IFN-g-
induced DNA-binding proteins (43). We analyzed STAT activa-
tion by IL-5 through the measurement of luciferase activity. As
can be seen in Fig. 1, COS cells transfected with the pSG5
expression vector without STAT cDNAs showed an IL-5-de-
pendent 2-fold increase in luciferase activity, which is probably
due to endogenous STATs in COS cells. Overexpression of
hSTAT1a resulted in an IL-5-dependent 2-fold increase of lu-
ciferase activity compared with cells transfected with pSG5.
Surprisingly, IL-5 also activated hSTAT3, which resulted in a
14-fold increase of luciferase activity. As a control for ligand
specificity, we transfected COS cells with the cDNA for STAT3
and treated the cells with IFN-g. We observed that STAT3 was
not activated by IFN-g, whereas IFN-g was able to activate
STAT1a.2
Furthermore, we observed no effect of IL-5 on luciferase
activity after cotransfection of the cDNAs encoding for STAT4,
STAT5, and STAT6 (Fig. 1). These results show that IL-5 can
activate the transactivation potential of both STAT1a and
STAT3 in COS cells.
Since DNA-binding is a prerequisite for transactivation, we
tested nuclear extracts from untreated and IL-5-stimulated
COS cells transfected with STAT3. Indeed, when COS cells
were stimulated with IL-5 for 30 min, a single DNA binding
complex is induced using the ICAM-1 pIRE as a probe (Fig. 2).
2 E. Caldenhoven and R. de Groot, unpublished observation.
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This is a specific binding complex because it could be competed
with an excess of unlabeled pIRE, whereas a nonspecific com-
petitor (SP1) was unable to compete for binding. To confirm
that this DNA-binding protein was STAT3, we preincubated
nuclear extracts with antibodies against STAT3. As shown in
Fig. 2, this antibody against STAT3 binds to the DNA-protein
complex and is therefore not able to migrate into the gel. In
contrast, a control preincubation with STAT1a antibodies had
no effect on this DNA-protein complex. These results indicate
that IL-5 activates STAT3 binding to the ICAM-1 pIRE.
We further characterized the DNA-binding specificity of the
IL-5-induced STAT3 complex. These experiments were per-
formed with nuclear extracts from COS cells transfected with
the IL-5R and STAT3 and treated with IL-5 for 30 min. The
ICAM-1 pIRE was used as a radioactive probe, and as compet-
itors we used the IFN-g activating site elements from the c-fos
(SIEm67) (40) and the FcgRI promoter (GRR) (41). Fig. 3A
shows that competition with a 50-fold molar excess of either the
pIRE or SIEm67 oligonucleotides completely inhibited binding
of STAT3 to the ICAM-1 pIRE, whereas a mutant ICAM-1
pIRE was unable to compete for binding. Competition with the
GRR sequence resulted in a decrease of STAT3 binding to the
pIRE, suggesting that the pIRE is a better binding site for
STAT3 than the GRR. We also tested the transcriptional activ-
ity of STAT3 mediated on the GRR sequence. We therefore
inserted four copies of the GRR sequence in front of a tkCAT
reporter plasmid. This 4xGRRtkCAT reporter construct was
transfected in COS cells together with cDNAs encoding the
IL-5Ra and bc subunits and STAT3. As shown in Fig. 3B,
overexpression of the IL-5R and STAT3 in the presence of IL-5
resulted in a 40-fold induction of luciferase activity mediated
via the GRR sequence. The increase in luciferase activity is
comparable with the IL-5-induced transactivation of a
4xpIREtkCAT reporter construct. Taken together, these re-
sults show that IL-5 is capable of activating STAT3 in COS
FIG. 1. Transactivation by STAT3 is induced in response to
hIL-5.Monkey COS cells were transiently transfected by calcium phos-
phate precipitation with 2 mg of 2xIREtkluc reporter construct, 0.5 mg
of hIL-5Ra cDNA, 0.5 mg of hIL-5Rb cDNA, 4 mg of pSG5 (lane 1), 4 mg
of hSTAT1a cDNA (lane 2), 4 mg of hSTAT3 cDNA (lane 3), 4 mg of
mSTAT4 cDNA (lane 4), 4 mg of shSTAT5 cDNA (lane 5), 4 mg of
hSTAT6 cDNA (lane 6) and 2 mg of a b-galactosidase expression vector
(pSV-lacZ) as a control for transfection efficiency. 1 day after transfec-
tion, cells were incubated for 16 h with IL-5. The cells were then
harvested, and b-galactosidase and luciferase activities were deter-
mined. Luciferase activities were normalized to b-galactosidase activi-
ties. -Fold induction of luciferase activity in IL-5 treated (gray bars)
compared with untreated control cells (black bars) is shown. Values
represent the averages of four different experiments 6 S.E. IL-5 clearly
enhances IL-6/IFN-g response element activation by STAT1a and
STAT3.
FIG. 2. hIL-5 induces a DNA binding complex containing
STAT3. The hIL-5 receptor and STAT3 were expressed in COS cells.
These cells were either untreated or treated for 30 min with IL-5, after
which nuclear extracts were prepared. Nuclear extract were assayed for
binding to the 32P-labeled ICAM-1 pIRE in bandshift experiments. For
competition experiments, extracts were preincubated for 5 min with a
50-fold molar excess of unlabeled oligonucleotide as indicated. For iden-
tification of the STAT proteins, the extracts were incubated with either
anti-STAT1a, anti-STAT3 antibodies, or nonimmune serum for 30 min
before the addition of the 32P-labeled ICAM-1 pIRE. IL-5 clearly induces
binding of STAT3 to the ICAM-1 pIRE.
FIG. 3. hIL-5 induced STAT3 activity is not restricted to the
ICAM-1 pIRE. A, COS cells expressing the hIL-5 receptor and STAT3
were stimulated with IL-5 for 30 min. Nuclear extracts were prepared
and incubated with a 32P-labeled ICAM-1 pIRE. For competition exper-
iments, extracts were pre-incubated for 5 min with a 50-fold molar
excess of unlabeled oligonucleotide as indicated. IL-5-induced STAT3
can bind to other STAT binding sites. B, COS cells were transient
transfected with the IL-5Ra, IL-5Rb, and STAT3 cDNAs together with
either a 4xIREtkCAT or a 4xGRRtkCAT reporter construct. 1 day after
transfection, cells were stimulated with IL-5 and harvested after 16 h.
Chloramphenicol acetyltransferase assays were performed with b-ga-
lactosidase-normalized samples, and -fold induction was calculated rel-
ative to untreated cells. Values represent the averages of three different
experiments 6 S.E. IL-5 induces activation of both IRE- and GRR-
containing promoters by STAT3.
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cells.
IL-5 Induces Tyrosine Phosphorylation and DNA Binding of
STAT3 in BaF3/IL5R Cells—Since the results described above
were obtained using transiently transfected cells overexpress-
ing STAT3, we next addressed the question of whether endog-
enous STAT3 could be activated by hIL-5. For this purpose, we
used the IL-3-dependent murine pro B-cell line BaF3, which we
stably transfected with the human IL-5Ra and bc subunits
(BaF3/IL5R). Since tyrosine phosphorylation of STAT proteins
is rapidly induced after cytokine stimulation, we immunopre-
cipitated STAT3 from unstimulated and hIL-5-stimulated
BaF3/IL5R cells. Tyrosine phosphorylation of STAT3 was then
monitored by Western blotting using the antiphosphotyrosine
antibody 4G10. As shown in Fig. 4A, stimulation with hIL-5
resulted in phosphorylation of the STAT3 protein.
Subsequent to tyrosine phosphorylation, STATs dimerize
and translocate to the nucleus were they bind to specific DNA
sequences. Therefore, nuclear extracts from untreated and hIL-
5-stimulated BaF3/IL5R cells were incubated with a 32P-la-
beled pIRE oligonucleotide and analyzed in a bandshift assay.
Fig. 4B shows that stimulation with hIL-5 for 15 min results in
the formation of four binding complexes. The same complexes
were observed in mouse IL-3-treated parental BaF3 cells.2 To
determine the identity of the DNA binding proteins induced by
hIL-5, we preincubated nuclear extracts with antibodies
against STAT1a and STAT3. We found that anti-STAT1a an-
tibodies diminished complex C2 and C3, whereas anti-STAT3
antibodies blocked the formation of complex C1 and C2 (Fig.
4B). The upper complex C4 was not affected by either STAT1a
or STAT3 antibodies. We conclude from these data that in
BaF3/IL5R cells, hIL-5 activates both STAT1a and STAT3,
which bind both as homo- and heterodimers to the ICAM-1
pIRE.
The Membrane Proximal Region of the a Subunit and the
Box1 Region of the bc Subunit Are Required for STAT3 Activa-
tion—The high affinity receptor for IL-5 is composed of a li-
gand-specific a subunit and a bc subunit that plays an impor-
tant role in transducing signals to the cytoplasm (17, 21).
Previously, it was demonstrated that JAK2 is constitutively
associated with the bc subunit (29). In particular, the mem-
brane proximal region, which contains the box1 motif, which is
also present in other cytokine receptors, is required for JAK2
activation. Furthermore it has been noticed that a specific
tyrosine-based motif in the gp130 receptor is involved in
STAT3 activation (55). Since the bc subunit lacks such a spe-
cific tyrosine based motif, we were interested in determining
which region of the receptor is necessary for STAT3 activation.
For this purpose, we generated a series of cytoplasmic trunca-
tions of the bc subunit. A schematic representation of these
constructs is depicted in Fig. 5A. We transfected COS cells with
these bc subunit deletion mutants in combination with the wild
type IL-5a subunit, STAT3, and the reporter plasmid 2xpIREt-
kluc (Fig. 5B). We found that the bc, b826, b762, b627, and
b516 each were able to mediate STAT3 activation in response
to IL-5. However, the transactivation potential of construct
b516 was diminished with 50%, indicating that the region
between 516 and 627 is necessary for optimal STAT activation.
By contrast, no STAT3 activation was observed when the most
truncated b456 receptor mutant was expressed. Consistent
with these data was the observation that the internal deletion
mutant b457–543 was not capable of activating STAT3 in re-
sponse to IL-5. Another internal deletion mutant, b518–543,
which still contains box2, clearly activated STAT3. These re-
sults suggests that the region between amino acids 452 and 516
containing box1 is required for both JAK2 and STAT3 activa-
tion, whereas the region between amino acids 543 and 627
plays an additional role in STAT3 activation. We further con-
clude from these experiments that tyrosine phosphorylation of
the bc receptor is not necessary for STAT3 activation, since the
b516 receptor deletion mutant is still able to activate STAT3,
although this truncated receptor contains no intracellular ty-
rosine phosphorylation sites.
We next examined whether the cytoplasmic domain of the
hIL-5Ra is involved in STAT3 activation. A schematic repre-
sentation of the constructed carboxyl-terminal a subunit mu-
tants a405, a390, and a366 is shown in Fig. 5A. Transfection of
COS cells with these truncated a receptor mutants together
with the wild type bc subunit shows that only mutant a366 was
unable to mediate STAT3 activation (Fig. 5C). This region
between amino acids 366 and 390 contains a proline-rich re-
gion, which has some similarity with the box1 region in other
receptors. Furthermore, it has been shown that this region is
necessary for JAK2 activation, although JAK2 is not associated
with the a subunit (17, 29). Taken together, we found that the
cytoplasmic proline-rich region of IL-5Ra and the box1 region
of the bc subunit are essential for STAT3 activation.
DISCUSSION
Our results demonstrate that besides STAT1a and STAT5
(27, 36, 37), STAT3 also plays a role in IL-5 signal transduc-
tion. This extends the list of cytokines that are capable to
activate the STAT3 protein (32, 56, 57). STAT3 was originally
identified as the acute phase response factor, which is activated
in response to IL-6 and plays a role in the activation of the
acute phase response genes (58). Later on it became clear that
this protein shows homology (40–50%) to STAT1a/b (32) and
FIG. 4. Tyrosine phoshorylation and activation of STAT3 by
hIL-5 in BaF3/IL5R cells. BaF3 cells stably expressing the hIL-5
receptor (BaF3/IL5R) were untreated or treated with hIL-5 for 15 min.
A, endogenous STAT3 was immunoprecipitated from these BaF3/IL5R
cells with a monoclonal antibody specific against STAT3. Immunopre-
cipitates were analyzed by Western blotting with the phosphotyrosine-
specific antibody 4G10 (left panel). The membrane was stripped and
reprobed with the STAT3 specific antibody (right panel). hIL-5 clearly
induces phosporylation of STAT3 on tyrosine residues. B, nuclear ex-
tracts from these BaF3/IL5R cells were analyzed in a bandshift assay
using the ICAM-1 pIRE as a probe. The extracts from hIL-5-stimulated
cells were incubated with either anti-STAT1a, anti-STAT3 antibodies,
or nonimmune serum. The hIL-5-induced pIRE binding complex con-
tains both STAT1a and STAT3.
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FIG. 5. Analysis of c-terminally truncated hIL-5 receptor mutants for STAT3 activation. A, schematic representation of the wild type
and carboxyl-terminal deletions mutants of the hIL-5 receptor a and bc subunits. The box1/2 homology regions are shown for the bc chain. A
proline-rich region of homology between the a subunits of receptors for GM-CSF, IL-3, and IL-5 is also shown. B, COS cells were transiently
transfected with the wild type hIL-5Ra together with the wild type human bc chain or one of the bc chain deletion mutants. Furthermore, the
expression vectors for STAT3 and a b-galactosidase and the 2xpIREtkluc reporter plasmid were co-transfected. 1 day after transfection, cells were
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was therefore renamed STAT3.
The studies presented here demonstrate that STAT3 is acti-
vated in response to IL-5 both at the DNA-binding and tran-
scription-activation level. We performed these experiments in
COS cells by reconstitution of the IL-5R together with several
members of the STAT family. We found that IL-5 induces
specifically the transactivation potential of STAT1a and
STAT3 mediated via the pIRE. Although we were not able to
detect an effect of IL-5 to activate the transcriptional potential
of STAT5, we found an IL-5-induced increase in DNA-binding
of STAT5 to the GRR.2 The latter finding is in line with recent
studies, which demonstrated an increase in DNA-binding but
not in transactivation mediated by mSTAT5 in response to
growth hormone and erythropoietin in COS cells (37). This
means that probably cell type-specific factors play an addi-
tional role in the transactivation of the STAT proteins. We
reported recently that serine phosphorylation is necessary to
mediate STAT3 transactivation (45). Because IL-5 plays a re-
stricted role in hematopoiesis, it can be envisaged that cell
type-specific serine/threonine kinases are necessary to activate
the transactivation potential of some STAT proteins. A recent
report showed induced tyrosine phosphorylation of STAT6 by
IL-3 in murine IL-3-dependent myeloid DA-3 cells (39). Al-
though IL-3 and IL-5 use the common bc subunit, we found no
activation of STAT6 by IL-5 after overexpression of STAT6 in
COS cells. This observation also supports the hypothesis that
cell type-specific factors are required for STAT activation. The
involvement of STAT3 in IL-5 signaling is further supported by
the observation that STAT3 was tyrosine phosphorylated in
BaF3/IL5R cells after treatment with hIL-5. The tyrosine phos-
phorylation of STAT3 is necessary for binding of the STAT3
protein to the ICAM-1 pIRE as can be seen in Fig. 4B. We found
that hIL-5 induced four DNA-binding complexes in these BaF3/
IL5R cells. Using different STAT antibodies, we identified com-
plex C1 as a STAT3 homodimer, complex C2 as a STAT1a/
STAT3 heterodimer, and C3 as a STAT1a homodimer, whereas
C4 was not supershifted by both antibodies. Recently a similar
DNA binding pattern was found when human breast carcinoma
T47D cells were treated with IL-6. However, they identified the
C4 complex as a multimeric complex composed of STAT3, a
91-kDa (not STAT1a), and a 46-kDa protein (59). In conclusion,
IL-5 activates both STAT1a and STAT3 in COS and BaF3 cells.
However, the previously described unidentified DNA-binding
protein induced by IL-5 in mature human eosinophils was not
recognized by a STAT3 antibody.2 The activation of different
STAT proteins by a single cytokine such as IL-5 provides the
cell with a mechanism to activate different subsets of target
genes depending on the cellular context. For example, STAT3
might play a role in the precursor cells of the eosinophil. This
hypothesis is presently tested by differentiating hematopoietic
stem cells from cord blood with IL-5 to mature eosinophils.
Signal transduction by the IL-5 receptor is rather poorly
characterized. The cytoplasmic domain of the bc subunit is well
characterized in the context of the GM-CSF receptor and con-
tains two distinct regions that are responsible for different
signals (19). A membrane proximal region of the approximately
60 amino acids is essential for induction of the c-myc and pim-1
genes as well as for inducing mitogenesis. A distal region of 140
amino acid residues is required for activation of Ras, Raf-1,
mitogen-activated protein kinase and p70 S6 kinase. Recently,
it has been shown that a cytoplasmic portion containing box1 of
the bc subunit is required for JAK2 activation. Moreover, JAK2
is constitutively associated with the membrane proximal re-
gion of the bc chain (29). Deletion analysis of the receptors for
growth hormone, erythropoietin, and the interleukin-6 receptor
signal transducing protein gp130, showed an absolute require-
ment of a six amino acid PXXPXP sequence in box1 for JAK
kinase association (60). Furthermore, a proline-rich region in
the IL-5a receptor that resembles box1 in the bc subunit is also
important for JAK2 activation (17), although JAK2 is not as-
sociated with this region (29). However, not much is known
about the involvement of the IL-5R in the activation of STAT
proteins. Our results using a series of c-terminally truncated
deletion mutants of the a and b chain demonstrate that the
membrane-proximal region of both subunits are required for
STAT activation. Recently, the involvement of a specific ty-
rosine-based motif in the gp130 receptor has been described in
the phosphorylation of STAT3 (55). However, receptor deletion
mutant b516 contains no tyrosine phosphorylation sites but
was still able to activate STAT3. This means that tyrosine-
phosphorylation of the bc subunit is not important for STAT3
activation. The same observation was previously shown for
STAT1a activation accomplished via the growth hormone re-
ceptor (61). An alternative mechanism could be that the SH2
domain of the STAT3 protein binds to the tyrosine-phosphoryl-
ated JAK kinase, or that the SH3 domain of STAT3 binds to the
proline-rich box1 region of the bc subunit. Such a mechanism
can be explained by the requirement of the membrane-proxi-
mal region of the bc subunit for both JAK and STAT activation.
This suggests that the precise mechanism by which STAT
proteins are activated probably depends on the association of
the different JAK kinases to cytokine receptors and on specific
binding sites for STAT proteins on the cytokine receptor.
Therefore, further studies are required to determine the pre-
cise molecular mechanism by which STAT proteins are acti-
vated via the bc subunit of the IL-5 receptor.
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